Corvus (CRVS) Q2 2026 earnings review
Clinical Execution Accelerates, but so does Cash Burn
Corvus is rapidly advancing its late-stage pipeline with soquelitinib, driving a significant acceleration in operational spend. R&D expenses doubled year-over-year to $16.0 million as the Phase 3 PTCL and Phase 2 SIERRA1 atopic dermatitis trials ramped up. Despite the surging burn rate, the massive $189.4 million capital raise from January 2026 provides a robust $215.2 million cash buffer, yielding an estimated runway into Q2 2028. The core story remains focused on clinical execution and upcoming readouts, though an unusual $5.0 million investment into their regional partner, Angel Pharmaceuticals, raises slight capital allocation questions.
🐂 Bull Case
Recent Phase 1 SID presentations confirmed safety and durability in atopic dermatitis, supporting the hypothesis that ITK inhibition can reset the immune system. Efficacy was seen even in treatment-resistant patients.
With $215.2M in cash equivalents following a major Q1 financing, Corvus is fully funded through multiple critical inflection points, removing the near-term financing overhang that plagued the stock in FY25.
🐻 Bear Case
Operating loss widened by 88% YoY to $19.3M this quarter. As the Phase 3 PTCL and multiple Phase 2 trials simultaneously enroll, cash burn is accelerating rapidly, which could threaten the Q2 2028 runway guidance if costs spiral.
While trials are enrolling, major data readouts for the SIERRA1 Phase 2 and PTCL Phase 3 trials are not expected until late 2026 or 2027, leaving the stock vulnerable to broad biotech market volatility in the interim.
⚖️ Verdict: ⚪
Neutral. Corvus has the necessary capital and a scientifically compelling asset in soquelitinib. However, execution risk is peaking as the company transitions to managing simultaneous, resource-intensive global trials, reflected in the aggressively accelerating R&D spend.
Key Themes
Atopic Dermatitis Advancement (SIERRA1)
Corvus is actively enrolling the 200-patient SIERRA1 Phase 2 trial for soquelitinib in moderate-to-severe atopic dermatitis. The trial is evaluating three dose regimens (200 mg QD, 200 mg BID, 400 mg QD) against placebo. Recent presentations at the Society for Investigative Dermatology (SID) highlighted positive Phase 1 clinical and biomarker data, validating the mechanism of increasing persistent Treg cells to affect inflammatory pathways. This is the company's primary value driver in the broader immunology market.
Accelerating R&D Expenditure
Operating expenses are accelerating aggressively. R&D spend hit $16.0M this quarter, up 102% YoY from $7.9M in 25Q2, driven by the simultaneous execution of the Phase 3 PTCL trial, the Phase 2 SIERRA1 trial, and preparation for new Phase 2 trials. Management claims the cash runway stretches to Q2 2028, but if this trajectory of quarterly burn escalation continues, that timeline may prove overly optimistic.
Pipeline Expansion into Large Immunology Markets
Management is leaning into the broad macro opportunity of the immunology and inflammation (I&I) market. Leveraging soquelitinib's unique ITK inhibition mechanism, Corvus plans to initiate new Phase 2 trials in hidradenitis suppurativa and asthma later this year. By showing utility across multiple Th2 and Th17 mediated diseases, Corvus aims to position the drug as a 'pipeline in a product'.
Unusual Partner Funding Dynamics
Corvus reported investing $5.0 million into a $13.5 million equity financing for its Chinese partner, Angel Pharmaceuticals. Typically, regional out-licensing deals are designed to bring non-dilutive capital into the primary developer, not drain it. While this funds Angel's Phase 1b/2 AD trial and a new asthma trial, it contradicts the positive narrative of capital efficiency and essentially means Corvus is subsidizing its own partner's clinical work.
Phase 3 PTCL Progress
The 150-patient registrational Phase 3 trial in relapsed/refractory peripheral T-cell lymphoma (PTCL) remains on track. Armed with FDA Orphan Drug and Fast Track designations, soquelitinib is being tested against standard chemotherapies (belinostat or pralatrexate). This remains the company's fastest potential path to commercialization.
Other KPIs
Stable quarter-over-quarter drop from $236.7 million in Q1, reflecting the baseline cash burn. This massive cash pile, generated largely from the $189.4M January financing, entirely de-risks the balance sheet for the medium term.
Net loss widened significantly from $8.0 million in the prior-year period. This includes non-cash losses of $0.7 million from the Angel Pharma equity investment.
Accelerating from $2.4 million a year ago. While modest compared to R&D, the combined increase in fixed and administrative costs underscores the organizational scale-up required to support late-stage clinical operations.
Guidance
Stable. The company reiterates that its $215.2M balance will fund operations for roughly 24 months. Achieving this implies an average quarterly burn rate of roughly $25-27 million going forward, allowing room for the recent R&D spikes to persist.
Stable. The company continues to guide for a 200-patient enrollment across four cohorts (3 active, 1 placebo) for a 12-week treatment period.
Stable. Results from Cohort 1 (100 mg BID and 200 mg QD) of the China-based atopic dermatitis trial are expected late this year, providing the next major near-term clinical data catalyst.
Key Questions
Angel Pharma Capital Requirements
Given the recent $5.0 million investment into Angel Pharmaceuticals, are there further obligations or expectations for Corvus to financially backstop the China-based clinical trials, or is Angel now fully self-sufficient?
R&D Expense Plateau
With R&D expenses doubling year-over-year to $16.0 million, have we reached the peak quarterly burn rate for the current trial roster, or should we model further sequential increases as the Phase 2 asthma and HS trials initiate?
SIERRA1 Enrollment Updates
Can management provide any color on the current enrollment pace for the SIERRA1 trial, and specifically when you anticipate concluding enrollment?